Leukoreduction Filters in Transfusion Medicine: 4 Factors That Matter Most
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, has shared a post on LinkedIn:
”Do all leukoreduction filters perform the same? Not really…
In transfusion medicine, not all filters are equal. Behind what looks like a simple device lie technical choices that directly impact patient safety and blood product quality. So… how do you know which one is the right filter?
Here are the 4 key criteria:
Leukoreduction performance
• European standard: ≤ 1 million residual white blood cells
• AABB standard: ≤ 5 million
In practice, users often expect a filter to perform 5 to 10 times better than these limits, to ensure stability and safety.
Residual losses
An efficient filter retains leukocytes… but it may also trap red blood cells. Too much loss = a direct impact on hemoglobin levels, or on the required minimum recovery (≥ 85% according to AABB). The challenge is to find the right balance.
Filtration speed
Some centers want ultra-fast processing. Others prefer quality over speed. It all depends on the number of units to process daily and the available “masked time.”
Final component quality
Filters also influence hemolysis in red blood cells or platelet activation in PC. An invisible variable… but one that determines therapeutic value.
Conclusion – there is no such thing as a “perfect” filter. The right filter is the one that fits your process, your priorities, and your patients.
And you, which of these criteria weighs the most in your decisions?”
Stay updated on the emerging in transfusion medicine with Hemostasis Today.
-
Jun 17, 2026, 11:45Advancing Patient-Centred Innovation in Thalassaemia Care at EHA2026 – TIF
-
Jun 17, 2026, 11:37Alessandro Lucchesi: Mechanistic Biology as the Engine of Next-Generation Therapies
-
Jun 17, 2026, 11:23Gabriela Hobbs: Emerging Myelofibrosis Therapies at EHA 2026
-
Jun 17, 2026, 09:54Shadi Tabibian: Improving Outcomes Through Accurate VWD Subclassification
-
Jun 17, 2026, 09:47Nihal Mesmoudi: Inspired by Scientific Excellence at ICMES 2026
-
Jun 17, 2026, 09:26Nicolas Gendron: Join the Conversation on Antithrombotic Stewardship at ISTH 2026
-
Jun 17, 2026, 09:19Natalia Schütz: Translating Scientific Advances into Better Patient Outcomes
-
Jun 17, 2026, 05:21Finn Guo: Exploring Payment Mechanisms for Innovative Hemophilia Therapies
-
Jun 17, 2026, 04:59Wolfgang Miesbach: One-Time CRISPR Therapy Reduces Hereditary Angioedema Attacks by 87%